Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC

• Váldodahkkit: Ceva Wicaksono Pitoyo (Dahkki), Cleopas Martin Rumende (Dahkki), Anindita Kartika Wiraputri (Dahkki), Fatira Ratri Audita (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Interna Publishing, 2022-04-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Alectinib is one of the targeted therapies commonly given to patients with advanced non-small cell lung cancer (NSCLC) with mutations in the ALK gene. The most common adverse effects of alectinib are fatigue, constipation, edema, myalgia and anemia. Meanwhile, bradycardia was reported as a very comm...